Pricing Log in Create free account

BridgeBio Pharma, Inc. (BBIO) vs Summit Therapeutics PLC (SMMT)

BridgeBio Pharma, Inc. and Summit Therapeutics PLC are both Biotechnology companies. BridgeBio Pharma, Inc. is the larger, with a market value of $14.5B against $11.3B — 1.3× the size. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 167.3% against −61.0%. Summit Therapeutics PLC has the higher net margin (0.00% vs −62.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, BridgeBio Pharma, Inc. leads on 11 and Summit Therapeutics PLC on 5.

Valuation

Metric BBIO SMMT Biotechnology median
P/E n/m n/m 10.26
P/S 15.49 15,883.80 9.18
P/B n/m 17.78 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 15.90 15,045.51 8.98
Earnings yield (4.07%) (7.78%) (34.89%)
Free cash flow yield (2.58%) (4.11%) (24.52%)

Profitability

Metric BBIO SMMT Biotechnology median
Gross margin 94.34% 100.00% 65.16%
Operating margin (38.52%) 0.00% 0.00%
Net margin (62.62%) 0.00% 0.00%
Free cash flow margin (39.11%) 0.00% 0.00%
Return on equity 26.22% (192.50%) (50.12%)
Return on assets (37.48%) (159.09%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BBIO SMMT Biotechnology median
Revenue growth (TTM) 167.27% (61.03%) 6.26%
EPS growth (last fiscal year) (31.25%) (364.52%) 29.88%
Revenue growth, 5-year CAGR 127.44% (46.49%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BBIO SMMT Biotechnology median
Debt to equity (1.17) 0.00 0.00
Current ratio 2.09 6.96 4.89
Net debt to EBITDA (2.47) 0.65 1.01

Dividend

Metric BBIO SMMT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BBIO SMMT Biotechnology median
Market cap 14.47b 11.32b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack